cAMP-dependent protein kinase catalytic subunit gamma (PRKACG)

cAMP-dependent protein kinase catalytic subunit gamma (PRKACG) is an enzyme encoded by the PRKACG gene in humans[1][2]. It represents one of several catalytic subunits of the protein kinase A (PKA) holoenzyme, which is pivotal in mediating cellular responses to elevated cyclic AMP (cAMP) levels. PKA is composed of two regulatory and two catalytic subunits, of which PRKACG encodes the gamma isoform of the catalytic component[1][2][3]. Activation of PKA occurs when intracellular cAMP levels rise, causing dissociation of the catalytic subunits from the regulatory dimer and unleashing kinase activity to phosphorylate a broad range of cytoplasmic and nuclear substrates. PRKACG, like other PKA catalytic subunits, is implicated in essential signaling pathways that regulate energy metabolism, cell proliferation, and gene transcription, through phosphorylation of serine and threonine residues on target proteins[2][3]. The gene is intronless and believed to be a retrotransposon derivative of the gene for the alpha catalytic subunit (PRKACA)[1][3]. PRKACG has disease associations including rare bleeding disorders and is implicated in various metabolic and signaling cascades[2]. The structural and enzymatic properties of PRKACG are closely aligned with other PKA subunits, and while the majority of research/drug targeting is focused on the entire PKA complex or its major subunits (Cα, Cβ), PRKACG is recognized as a functional enzyme with clinical relevance. Note: Most drug modulators, clinical safety data, and biomarker information pertain to PKA as a whole rather than PRKACG specifically, reflecting the highly conserved and redundant nature of the PKA catalytic subunits within the enzyme complex[2][3].

Other names

PRKACGPKA C-gammaPKACgBDPLT19KAPGcAMP-dependent protein kinase catalytic subunit gammaprotein kinase cAMP-activated catalytic subunit gammaprotein kinase, cAMP-dependent, catalytic, gamma subunitserine(threonine) protein kinase, PRKACG

Small molecule kinase inhibitors: Compounds that inhibit kinase catalytic activity by binding to the ATP site. cAMP activators: Indirect modulation of activity via increase in intracellular cAMP, resulting in subunit activation and subsequent substrate phosphorylation. Notably, most modulators target the PKA holoenzyme or cAMP pathway, not individual subunits.